Anthonye Lang News Today

Scientists propose a new model for classifying Parkinson’s. The complexity of Parkinson's disease poses significant challenges in developing effective treatments. This complexity stems from various causes, including genetics and environmental factors, coupled with the broad spectrum of symptoms tha

The monoclonal antibodies cinpanemab and prasinezumab show almost no benefit for early Parkinson disease.

The monoclonal antibodies cinpanemab and prasinezumab show almost no benefit for early Parkinson disease.

Two studies show lack of benefit in primary or secondary end points with cinpanemab or prasinezumab versus placebo.